Compare
Erasca, Inc. vs Ironwood Pharmaceuticals Inc vs Harrow, Inc. vs Nkarta, Inc.
| Latest fiscal year | Erasca, Inc. ERAS | Ironwood Pharmaceuticals Inc IRWD | Harrow, Inc. HROW | Nkarta, Inc. NKTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $296.15M | $272.30M | $0 |
| Revenue growth (YoY) | n/a | -15.7% | +36.4% | n/a |
| Gross margin | n/a | n/a | 75.1% | n/a |
| Operating margin | n/a | 33.3% | 11.2% | n/a |
| Net margin | n/a | 8.1% | -1.9% | n/a |
| Net income | -$124.55M | $24.02M | -$5.14M | -$104.08M |
| EPS (Diluted) | -$0.44 | $0.15 | -$0.14 | -$1.41 |
| Operating cash flow | -$95.45M | $127.04M | $43.86M | -$88.70M |
| Free cash flow | -$95.58M | $127.01M | $42.98M | -$89.91M |
| Cash & equivalents | $73.81M | $215.46M | $72.93M | $39.63M |
| Total assets | $396.15M | $396.90M | $399.48M | $404.21M |
| Total liabilities | $70.98M | n/a | $347.39M | $91.88M |
| Shareholders' equity | $325.17M | -$261.83M | $52.45M | $312.32M |
| Return on year-end equity | -38.3% | n/a | -9.8% | -33.3% |
| Shares outstanding | 284.16M | 163.06M | 37.23M | 71.08M |
Revenue, most recent five fiscal years
| Fiscal year | Erasca, Inc. | Ironwood Pharmaceuticals Inc | Harrow, Inc. | Nkarta, Inc. |
|---|---|---|---|---|
| Latest | n/a | $296.15M Ended 2025-12-31 | $272.30M Ended 2025-12-31 | $0 Ended 2025-12-31 |
| 1 year earlier | n/a | $351.41M Ended 2024-12-31 | $199.61M Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | n/a | $442.74M Ended 2023-12-31 | $130.19M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $410.60M Ended 2022-12-31 | $88.59M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $413.75M Ended 2021-12-31 | $72.48M Ended 2021-12-31 | n/a |